Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Gains from Investment Securities (2021 - 2023)

Werewolf Therapeutics (HOWL) has disclosed Gains from Investment Securities for 2 consecutive years, with $136000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Gains from Investment Securities rose 111.23% to $136000.0 in Q4 2023 year-over-year; TTM through Sep 2023 was -$1.3 million, a 211.88% decrease, with the full-year FY2022 number at -$7000.0, changed N/A from a year prior.
  • Gains from Investment Securities was $136000.0 for Q4 2023 at Werewolf Therapeutics, up from -$136000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $1.2 million in Q2 2022 to a low of -$1.2 million in Q4 2022.